Inhibiting Signaling that Drives Growth of Rare Malformations

25:33
 
공유
 

Manage episode 271770003 series 60790
Player FM과 저희 커뮤니티의 RARECast 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.

Venous and lymphatic malformations are types of congenital vascular anomalies that are present at birth. These malformations can cause a number of complications including pain, bleeding, and impairment of the affected area. Current treatments options are limited and there are no drugs approved for these conditions. Venthera, a BridgeBio affiliate, is developing a topical gel for the treatment of venous and lymphatic malformations that targets signaling pathways that drive them. We spoke to Thom Rossi, CEO of Venthera, about the company’s lead experimental therapy, its first-in-man-trial, and how it is leveraging the resources of BridgeBio.

313 에피소드